In a secondary analysis of 159 patients with early triple negative breast cancer from the phase 2 c-TRAK TN study, tissue-free ctDNA detection (34.0%) was strongly prognostic for recurrence (HR 27.2), with median lead times similar to a multivariant tumour-informed assay.
Secondary analysisn = 159
Cunningham et al. Tissue-Free vs Tumor-Informed ctDNA Assays for Molecular Residual Disease Detection in Early Triple Negative Breast Cancer